{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:33:00Z","timestamp":1788406380462,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03622-8","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:52:33Z","timestamp":1753271553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5397-1482","authenticated-orcid":false,"given":"Rangi","family":"Kandane-Rathnayake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worawit","family":"Louthrenoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CS","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laniyati","family":"Hamijoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacai","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue Fen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelynn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sargunan","family":"Sockalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BMDB","family":"Basnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Pek Ling Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sapsford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih Jia","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherica","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne O\u2019Donnell","family":"Lefeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Shisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"3622_CR1","doi-asserted-by":"crossref","unstructured":"Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A et al. Comparison of attainment and protective effects of lupus low disease activity state in patients with newly diagnosed versus established systemic lupus erythematosus. J Rheumatol. 2024.","DOI":"10.3899\/jrheum.2023-0900"},{"key":"3622_CR2","doi-asserted-by":"crossref","unstructured":"Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen YH, Cho J et al. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study. Lancet Rheumatol. 2024.","DOI":"10.1016\/S2665-9913(24)00121-8"},{"issue":"1","key":"3622_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","volume":"24","author":"R Kandane-Rathnayake","year":"2022","unstructured":"Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, et al. Not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70.","journal-title":"Arthritis Res Ther"},{"key":"3622_CR4","doi-asserted-by":"crossref","unstructured":"Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023.","DOI":"10.1136\/ard-2022-222748"},{"key":"3622_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand E, Pike M, Merrill JT, van Vollenhoven R, Werth VP, Hobar C, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, Double-Blind, Placebo-Controlled trial. Arthritis Rheumatol. 2023;75:242\u201352.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3622_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12016-020-08817-2","volume":"60","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Zhou Z, Zhao L, Fei Y, Chen H, et al. Management of severe refractory systemic lupus erythematosus: Real-World experience and literature review. Clin Rev Allergy Immunol. 2021;60(1):17\u201330.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"3622_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40265-022-01824-x","volume":"83","author":"D Roccatello","year":"2023","unstructured":"Roccatello D, Sciascia S, Rossi D, Fenoglio R. Refractory systemic lupus erythematosus: identification and Pharmacological management. Drugs. 2023;83(2):117\u201334.","journal-title":"Drugs"},{"issue":"9","key":"3622_CR8","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1093\/rheumatology\/keab003","volume":"60","author":"A Hoi","year":"2021","unstructured":"Hoi A, Nim HT, Koelmeyer R, Sun Y, Kao A, Gunther O, et al. Algorithm for calculating high disease activity in SLE. Rheumatology (Oxford). 2021;60(9):4291\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"3622_CR9","doi-asserted-by":"crossref","unstructured":"Koelmeyer R, Nim HT, Nikpour M, Sun YB, Kao A, Guenther O et al. High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Sci Med. 2020;7(1).","DOI":"10.1136\/lupus-2019-000372"},{"issue":"8","key":"3622_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Volkl S, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"3","key":"3622_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/1756-185X.13431","volume":"22","author":"R Kandane-Rathnayake","year":"2019","unstructured":"Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, et al. Development of the Asia Pacific lupus collaboration cohort. Int J Rheum Dis. 2019;22(3):425\u201333.","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"3622_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3622_CR13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3622_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acr.20648","volume":"64","author":"MB Urowitz","year":"2012","unstructured":"Urowitz MB, Gladman DD, Ibanez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012;64(1):132\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"3622_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1191\/096120399680411335","volume":"8","author":"DD Gladman","year":"1999","unstructured":"Gladman DD, Urowitz MB. The SLICC\/ACR damage index: progress report and experience in the field. Lupus. 1999;8(8):632\u20137.","journal-title":"Lupus"},{"issue":"1","key":"3622_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203310385163","volume":"20","author":"Z Touma","year":"2011","unstructured":"Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20(1):67\u201370.","journal-title":"Lupus"},{"issue":"2","key":"3622_CR17","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"12","key":"3622_CR18","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","volume":"59","author":"E Chessa","year":"2020","unstructured":"Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Arnaud L. Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology (Oxford). 2020;59(12):3622\u201332.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3622_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/ard.2010.132068","volume":"70","author":"DA Isenberg","year":"2011","unstructured":"Isenberg DA, Allen E, Farewell V, D\u2019Cruz D, Alarcon GS, Aranow C, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011;70(1):54\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"12 Pt 1","key":"3622_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","volume":"142","author":"JP Buyon","year":"2005","unstructured":"Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined Estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142(12 Pt 1):953\u201362.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3622_CR21","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo SF, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1(2):e95\u2013102.","journal-title":"Lancet Rheumatol"},{"key":"3622_CR22","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1).","DOI":"10.1136\/annrheumdis-2021-eular.1192"},{"issue":"10","key":"3622_CR23","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"key":"3622_CR24","doi-asserted-by":"crossref","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024:ard\u20132024.","DOI":"10.1136\/ard-2024-225785"},{"key":"3622_CR25","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez JC, Barba P, \u00c1lvaro-Gracia \u00c1lvaro JM, Kwon M, Weinmann-Menke J, Wagner-Drouet E et al. Interim results of an open-label, multicentre, phase 1\/2 study to assess YTB323 (rapcabtagene autoleucel), a CAR T-cell therapy, for severe refractory systemic lupus erythematosus. Lupus Sci Med. 2024;11.","DOI":"10.1136\/lupus-2024-el.222"},{"key":"3622_CR26","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023;383:e073980.","journal-title":"BMJ"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03622-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:38:24Z","timestamp":1757277504000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03622-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03622-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each site obtained local ethics approval to participate in the APLC research activities. Storage of the central dataset and analyses of the pooled data have been approved by the Monash University Human Research Ethics Committee (MUHREC Project ID 18778). All patients enrolled in the APLC have provided informed consent use their data for APLC research activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Rangi Kandane-Rathnayake\u2013 has received grants from BMS, GSK, Janssen and NovartisWorawit Louthrenoo - NoneCS Lau - NoneLaniyati Hamijoyo - NoneJiacai Cho - NoneAisha Lateef - NoneShue Fen Luo - NoneYeong-Jian Wu - NoneSandra Navarra - has received consulting fees from AstraZeneca, Biogen, Boehringer Ingelheim and Idorsia, and payment for lectures from AstraZeneca, Boehringer Ingelheim, GSK and Roche.Leonid Zamora - NoneZhanguo Li - has received consulting fees and royalties from Abbott, AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, MSD, Novartis, Pfizer, Roche and UCB PharmaYi-Hsing Chen - NoneShereen Oon - NoneMadelynn Chan - NoneSargunan Sockalingam - NoneYanjie Hao - NoneZhuoli Zhang - NoneSang-Cheol Bae - supported in part by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2021R1A6A1A03038899)Jun Kikuchi - NoneYuko Kaneko - NoneTsutomu Takeuchi - NoneYasuhiro Katsumata - has received payment\/honoraria from Asahi Kasei Pharma, AstraZeneca K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd, GSK K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc. and Sanofi K.K. ZZ has received payment\/honoraria from AbbVie, AstraZeneca K.K., Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Novartis, Pfizer, Roche, Sanofi, Janssen, UCB Pharma, and has participated in advisory boards for Beigene Ltd.Duminda Basnayake - NoneFiona Goldblatt - was a Director on the Board of the Australian Rheumatology Association at the time of the study.Sean O\u2019Neill - NoneKristine (Pek Ling) Ng - NoneNicola Tugnet - NoneMark Sapsford - NoneYih Jia Poh - NoneCherica Tee - NoneMichael Tee - NoneNaoaki Ohkubo - NoneAdrianne O\u2019Donnell Lefeber\u2013 is an employee of NovartisTamas Shisha - is an employee of NovartisYoshiya Tanaka - has received speaking fees and\/or honoraria from Chugai, UCB, Abbvie, AstraZeneca, Eli-Lilly, Behringer-Ingelheim, GlaxoSmithKline, Eisai, IQVIA, Daiichi-Sankyo, Otsuka, Taisho, Gilead, Bristol-Mayers.Vera Golder - NoneMandana Nikpour - has received an Investigator Grant from the National Health and Medical Research Council of Australia (NHMRC GNT1176538), research grants from Boehringer Ingelheim and Janssen, consulting fees from AstraZeneca and GSK; honoraria for presentations from AstraZeneca, Boehringer Ingelheim and GSK, and support for conference attendance from Boehringer Ingelheim.Alberta Hoi - has received a research grant from AstraZeneca, consulting fees from EUSA Pharma (UK), GSK and UCB Australia, and speaker fees\/honoraria from AbbVie, Eli Lilly, Janssen, Limbic, Moose Republic and Novartis.Peter Gergely\u2013 is an employ of NovartisEric Morand - has received consulting fees from AbbVie, AstraZeneca, Biogen, Bristol Myers Squibb, Genentech, Gilead, Janssen, Novartis, and EMD Serono.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}